• Cho-A Pharmaceutical faces potential KOSDAQ “management issue” designation if its common-share market cap stays below KRW 20 billion.
• As of 2026-10-07, the market cap has remained under KRW 20 billion for 25 consecutive trading days.
• A further five consecutive trading days below the threshold from 2026-10-08 could trigger the designation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cho-A Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007900474), on October 07, 2026, and is solely responsible for the information contained therein.